S&P 500   5,069.53
DOW   39,069.23
QQQ   436.55
Is CRISPR Therapeutics the NVIDIA of gene editing?
Critical asset just had biggest fall on record (Ad)
3 Chinese stocks poised for rebound
4 stocks benefitting from NVIDIA's explosive growth
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
These 2 carnivore dining stocks gaining on the Ozempic craze
This healthcare stock making a buzz with 160% growth
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
First it was Tyson stock, now this food company is set to rally
How major US stock indexes fared Monday, 2/26/2024
S&P 500   5,069.53
DOW   39,069.23
QQQ   436.55
Is CRISPR Therapeutics the NVIDIA of gene editing?
Critical asset just had biggest fall on record (Ad)
3 Chinese stocks poised for rebound
4 stocks benefitting from NVIDIA's explosive growth
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
These 2 carnivore dining stocks gaining on the Ozempic craze
This healthcare stock making a buzz with 160% growth
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
First it was Tyson stock, now this food company is set to rally
How major US stock indexes fared Monday, 2/26/2024
S&P 500   5,069.53
DOW   39,069.23
QQQ   436.55
Is CRISPR Therapeutics the NVIDIA of gene editing?
Critical asset just had biggest fall on record (Ad)
3 Chinese stocks poised for rebound
4 stocks benefitting from NVIDIA's explosive growth
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
These 2 carnivore dining stocks gaining on the Ozempic craze
This healthcare stock making a buzz with 160% growth
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
First it was Tyson stock, now this food company is set to rally
How major US stock indexes fared Monday, 2/26/2024
S&P 500   5,069.53
DOW   39,069.23
QQQ   436.55
Is CRISPR Therapeutics the NVIDIA of gene editing?
Critical asset just had biggest fall on record (Ad)
3 Chinese stocks poised for rebound
4 stocks benefitting from NVIDIA's explosive growth
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
These 2 carnivore dining stocks gaining on the Ozempic craze
This healthcare stock making a buzz with 160% growth
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
First it was Tyson stock, now this food company is set to rally
How major US stock indexes fared Monday, 2/26/2024

Acelyrin (SLRN) Earnings Date, Estimates & Call Transcripts

$8.16
+0.75 (+10.12%)
(As of 02/26/2024 ET)
Skip Charts & View Estimated and Actual Earnings Data

SLRN Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

SLRN Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Acelyrin Analyst EPS Estimates

Current Year EPS Consensus Estimate:($7.40) EPS
Next Year EPS Consensus Estimate: ($4.38) EPS

SLRN Earnings Date and Information

Acelyrin has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, February 27th, 2024 based off prior year's report dates.

Acelyrin Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript
2/27/2024
Estimated)
------- 
11/7/2023Q3 2023($0.47)($0.87)($0.40)($0.87)--
8/14/2023Q2 2023($0.81)($0.56)+$0.25($0.72)--
6/15/2023Q1 2023($0.88)($2.11)($1.23)$4.39--












Acelyrin Earnings - Frequently Asked Questions

When is Acelyrin's earnings date?

Acelyrin has not confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, February 27th, 2024 based off last year's report dates. Learn more on SLRN's earnings history.

How much profit does Acelyrin generate each year?

Acelyrin (NASDAQ:SLRN) has a recorded net income of -$64.77 million. SLRN has generated $0.00 earnings per share over the last four quarters.

What is Acelyrin's EPS forecast for next year?

Acelyrin's earnings are expected to grow from ($7.40) per share to ($4.38) per share in the next year.


More Earnings Resources from MarketBeat

This page (NASDAQ:SLRN) was last updated on 2/27/2024 by MarketBeat.com Staff